Novel Agents in Pancreatic Cancer
This video covers the latest research in pancreatic cancer, including the possible role of PARP inhibitors, immunotherapy, and the novel drug PEGPH20.
In this video, Philip A. Philip, MD, PhD, of the Barbara Ann Karmanos Cancer Institute in Detroit, discusses the latest research developments and progress in the treatment of pancreatic cancer.
Philip touches on newer chemotherapy regimens such as FOLFIRINOX and gemcitabine plus nab-paclitaxel and highlights immunotherapy in this setting and targeted agents such as PARP inhibitors and a novel drug, pegylated recombinant human hyaluronidase (PEGPH20).
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
![“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F9b290688648a249e516474c175a3c06309426d15-2950x1568.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.")
Related Content
